Vasculitis & polymyalgia rheumatica
Subcutaneous Versus Intravenous Tocilizumab in Aortitis Associated With Giant Cell Arteritis: Multicenter Study of 196 Patients
Authors' conclusion
In this real-world cohort of GCA-associated aortitis, SC TCZ showed slightly greater effectiveness than IV TCZ in achieving EULAR-defined remission, whereas no significant differences were observed between both routes regarding imaging remission.
Study context
- Population
- Patients with giant cell arteritis (GCA)-associated aortitis diagnosed by imaging (18F-FDG PET/CT) and treated with tocilizumab (TCZ)148 women
- Participants
- 196 patients
- Exposure
- Subcutaneous (SC) TCZ vs intravenous (IV) TCZ
- SCn = 86
- IVn = 110reference
- Outcome
- Main outcomes: EULAR remission, clinical and imaging remission, absence of systemic inflammation, GC-sparing effect
- Follow-up
- 24 months
Methodological detailsmulticentre, real-world
- Multicentre
- Real-world
Main finding
As reported in the abstract
EULAR-defined remission
P < 0.05
Observational data: associations, not effects.
Original publication
Subcutaneous Versus Intravenous Tocilizumab in Aortitis Associated With Giant Cell Arteritis: Multicenter Study of 196 Patients. Arthritis Care Res (Hoboken). Published 18 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →